CN101686726A - Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs - Google Patents
Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs Download PDFInfo
- Publication number
- CN101686726A CN101686726A CN200880015561A CN200880015561A CN101686726A CN 101686726 A CN101686726 A CN 101686726A CN 200880015561 A CN200880015561 A CN 200880015561A CN 200880015561 A CN200880015561 A CN 200880015561A CN 101686726 A CN101686726 A CN 101686726A
- Authority
- CN
- China
- Prior art keywords
- calcium
- composition
- application
- weight
- butterfat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 239000011575 calcium Substances 0.000 title claims abstract description 72
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 235000021314 Palmitic acid Nutrition 0.000 title claims abstract description 23
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 230000032050 esterification Effects 0.000 title claims description 5
- 238000005886 esterification reaction Methods 0.000 title claims description 5
- 239000008267 milk Substances 0.000 title description 6
- 102000004169 proteins and genes Human genes 0.000 title description 4
- 108090000623 proteins and genes Proteins 0.000 title description 4
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 8
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 8
- 235000021239 milk protein Nutrition 0.000 claims abstract description 8
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 3
- 229960005069 calcium Drugs 0.000 claims description 70
- 235000013305 food Nutrition 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 102000011632 Caseins Human genes 0.000 description 20
- 108010076119 Caseins Proteins 0.000 description 20
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 20
- 239000005018 casein Substances 0.000 description 19
- 235000021240 caseins Nutrition 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- 239000003925 fat Substances 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 15
- 235000013365 dairy product Nutrition 0.000 description 13
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 8
- 102000004407 Lactalbumin Human genes 0.000 description 8
- 108090000942 Lactalbumin Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000000413 hydrolysate Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000005862 Whey Substances 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 235000020247 cow milk Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000002328 demineralizing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 241001119522 Paullinia pinnata Species 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- -1 aromatic amino acid Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
- A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of be used for making improve calcium absorb use combination of agents thing, described composition comprise preferred with palmitic acid at the bit esterified at least a butterfat of sn-2 and comprise at least a lactoprotein alternatively and/or at least a milk protein hydrolyzates.
Description
Technical field
The present invention relates to butterfat-milk protein composition is used for improving the application that calcium absorbs at human body.
Background technology
Because calcium deficiency is the pathogenesis of some typical disease of modern society, therefore human body being supplied with calcium is one of current most important target.
In whole life process, all need an amount of calcium to supply with.If, then can take place earlier, and when older, osteoporosis can take place to the bone undersupply at the early stage calcium of health not being supplied with capacity of infant.The deficiency that calcium is supplied with will cause the reduction of bone density.Yet before osteoporosis took place, calcium deficiency can cause metabolic very big disorder.Symptom is that the irritability of N﹠M increases, and this may cause muscle cramp.
People know for a long time, and breast is one of most important source of supplying with for human body calcium.Because relatively large calcium is contained in the Ruzhong, therefore all recommend conventional nutriment such as breast or dairy products about all relevant nutrition suggestions of replenishing the calcium.Yet, so far, it is very undesirable that the fat in Ruzhong is considered to, and one of reason is because in from the index information that consumes interested every profession and trade for plant fat, and butterfat is regarded as and source as the relevant material with negative properties such as cholesterol and saturated fatty acid.Result as new scientific discovery, considered the effect of the cholesterol in the food now in more complicated mode, meanwhile, because the quite a large amount of cholesterol in the human body is that health itself produces, therefore the edible food that contains cholesterol of appropriateness it is believed that it is that reasonably this viewpoint is generally accepted.
With chain length is the relevant negative effect of saturated fatty acid of 12~16 C atoms, and particularly relevant with the generation of vascular diseases negative effect is incontrovertible.Therefore, think that still butterfat (as the source of these aliphatic acid) is more worthless fat.
Up to the present prior art is all not too paid attention to butterfat natural containing and is not had structure in the plant fat, and this structure have only by corresponding modification (ester exchange) pay a large amount of effort with oriented approach from the plant fat manufacturing: this is called as " structured lipid ".
" structured lipid " is meant following fat and grease, wherein, the structure that changes triglycerides with oriented approach makes that (these positions are called as sn-1, sn-2 and sn-3 to three fatty acid radicals that are connected in glycerol molecule according to its position, wherein sn-1 and sn-3 are basic identical because of all being positioned at the outside, and sn-2 refers to the center all the time) with oriented approach generation ester exchange, its mode is to make some aliphatic acid mainly be present in the sn-2 position.There is the whole bag of tricks can realize above-mentioned situation, and has corresponding product: for example from the BETAPOL of Dutch Loders Croklaan B.V.Wormerveer company.This product that is obtained by vegetable oil by enzymic transesterification is used for feeding infant by special exploitation, and verified, and the calcium that has obtained to increase in the baby absorbs and surpassed 30% result.This product is characterised in that, the palmitic acid (C-16) that 45% the sn1/sn3 position that mainly appears at plant fat usually arranged approximately is present in sn-2 position in this product as the result of ester exchange.
Antipodal therewith is that plant fat and grease constitute (Porsgaard, T. and Hoy, CE, J.Nutr.130:1619-1624 (2000) with the form that palmitic acid does not see favourable sn-2 position (and being mainly seen in the sn-1/sn-3 position); Weber, N, etc., J.Nutr.133:435-441 (2003)).
These mechanism (by mistake) cause calcium to be absorbed in being in very disadvantageous situation among the human nutriology: as the result of above-mentioned " shortcoming " of butterfat, great majority are paid close attention to healthy crowd food plant fat but not butterfat.Meanwhile, to build and keep bone in order to take measures and to add calcium (for example as the salt in the nutritional supplement); Yet in these cases, owing in alimentary canal, form calcium soap, thereby have only 60% calcium to be absorbed by human body.Under slightly better situation, the still edible dairy products that are rich in calcium of people, but preferred low fat milk goods.Therefore, so very disadvantageous combination appearring more and more: wherein, particularly pays close attention to crowd's food plant fat (palmitic acid is positioned at the sn-1/sn-3 position) in edible calcium of nutrition.This combination has stoped the edible calcium of suitable vast scale to be absorbed by human body.
Though the infant nutrition scholar has promptly known principle (Lucas, A. etc., the Arch.Dis.Child 77:F178-F184 (1997) that prevents to form calcium soap in alimentary canal for many years; Nelson, CM and InnisSM., Am.J.Clin.Nutr.70:62-69 (1999); Ostrom KM. etc., J, Am Coll.Nutr.21:564-569 (2002)), but found that this principle can't be applied in the daily human nutrition in practice.In fact, document description is arranged calcium stoped absorbing again of fat and caused the absorption of fat in the alimentary canal to reduce (Jacobsen, R. thus by in alimentary canal, forming calcium soap; Lorenzen, J.K; Toubro, S.; Krog-Mikkelsen, I.; Astrup, A.; Intern.J.Obesity 29:292-301 (2005)).
In addition, point out also in the document that if desire realizes that calcium absorbs preferably, calcium must always provide with dairy products.Up to the present, (from cow's milk, have more than is from human milk to butterfat! ) fact that can make sizable contribution to this both specifically studied in the prior art and described, and also do not enter in people's the practical nutrition.
Summary of the invention
Therefore, the objective of the invention is to develop the product that can be used for optimizing human calcium's absorption.
Theme of the present invention is to use the composition manufacturing that contains at least a butterfat to improve calcium absorption reagent.
The invention is characterized in, can absorb by using the calcium that said composition significantly improves human body.This means and to avoid additionally using.
Butterfat is made of the butterfat component such as physical separation such as butter, perhaps is made of the newborn component that is rich in butterfat such as the milk wet goods.The butterfat of preferably from cow's milk, separating.Alternatively, can be used according to the invention take the butterfat of other animal species such as goat, sheep and camel freely.In addition, can improve these butterfat components from nutrition: can carry out heredity to ox for this reason and select, feed and/or can carry out classification to butterfat and handle (by crystallization targetedly) in mode targetedly by corresponding measure.
Therefore, be included in (wet goods of for example suckling) in the newborn component or can be used for butterfat used in the present invention by (for example butter) butterfat that the Ruzhong obtains by physical partition method.
Butterfat is preferably the newborn component of physical separation.In addition, described butterfat does not carry out such as any chemical changes such as ester exchanges.
Can change butterfat in the following manner by corresponding natural measure: make fatty acid profile and/or distribution of fatty acids in the triglyceride structure on physiology, embody more valuable characteristic.This promptly contains less palmitic acid altogether and/or has palmitic acid in the sn-2 position in triglycerides situation.Can realize the change of these parameters by the kind (Huo Sitan kind, west, pool kind or the blue kind of Fu Lisi etc.) of selection ox.Yet it is more effective to use the plant that has contained desired fats acid to carry out the specific aim nursing, and this is because many nutritious described aliphatic acid are directly incorporated into the Ruzhong.There are extensive studies (Palmquist, D.L. etc., J.Dairy Sci.76:1753-1771 (1993) about this respect; DePeters E.J. etc., J.Dairy Sci.84:929-936 (2001); Bell, J.A. etc., J.Dairy Sci.89:733-748 (2006); Allred S.L. etc., J.Dairy Sci.89:234-248 (2006); Nielsen, T.S. etc., Reprod.Nutr.Dev.46:699-712 (2006)).In the practice, for example exist to use rape, soybean and hybridization sunflower to change the way of fatty acid profile in the following manner: reduces nutritionally more disadvantageous saturated fatty acid (C12~C16) with for example significantly increase CLA.To mainly be combined in the butterfat with the palmitic acid (C16) that low ratio (seeing absolute quantity) is present in the butterfat in the sn-2 position.Also there are some researchs (DePeters E.J. etc., J.Dairy Sci.84:929-936 (2001) on the one hand about this; Porsgaard, T. and Hoy, CE, J, Nutr.130:1619-1624 (2000)).
A kind of diverse technology is the butterfat classification (Lai, H-C. etc., J.Dairy Sci.78:794-803 (1995)) by the specific aim crystallization.This technology makes to make and it is characterized by the much lower liquid butterfat component of palmitic acid content.This component is nutritionally also more favourable to human body.
The above-mentioned change of butterfat means can avoid all shortcomings that butterfat exists on the widely used road in healthy food, and the advantage of " the structured lipid character " of breast can be used for improve sanatory product that calcium absorbs.
The butterfat of composition used in the present invention preferably contains the esterification palmitic acid of 10%~50% (with respect to the percentage by weight of butterfat).Preferably in triglycerides used in the present invention there are 18 weight %~35 weight %, are preferably the palmitic acid of 22 weight %~28 weight % especially.The described palmitic acid of 20 weight %~75 weight % is arranged in the sn-2 position of glycerine (the palmitic acid total amount that exists with respect to triglycerides).The palmitic acid of preferred 35 weight %~50 weight %, preferred especially 40 weight %~45 weight % is positioned at the sn-2 position.
This means that in alimentary canal the palmitic acid on the glycerine keeps esterification (sn-2) (in alimentary canal at first from sn-1/sn-3 position separation of fatty acids), thereby described palmitic acid is not discharged but absorb as monoglyceride.This be because, palmitic acid and calcium in alimentary canal, formed be called calcium soap be not material that human body absorbed, and cause in the food quite that the calcium of vast scale (above 30%) is not absorbed by human body.This principle of avoiding calcium soap to form has been imitated breast milk, is connected in sn-2 position and known this lipid structure up to 80% palmitic acid and has sizable contribution for the very excellent absorption from the calcium of breast milk in breast milk.
Yet, use and also can realize this principle from the breast of other animal.For example, in cow's milk, there is 35%~55% palmitic acid also to be contained in the sn-2 position similarly approximately.Regrettably, until today cow's milk this character all be almost scientific circles and ignore (comparing) with breast milk.Animal breast (the most important thing is cow's milk for European crowd) contains quite a large amount of calcium, these calcium are utilized by the young man as far as possible effectively, thereby the Nature has been successfully by having created the directed sn-2 position that imports butterfat of palmitic acid the structured lipid of natural generation, and described structured lipid helps the good absorption from the calcium in Ruzhong.
Also surprisingly find, with calcium only is provided, only provides calcium with lactoprotein or only provide calcium to compare as the situation of food source with fat, if also use lactoprotein (and/or its subfraction) simultaneously except butterfat, composition then of the present invention can cause calcium absorption (surpassing 20%) in the much better body.In addition, verified when butterfat is combined with lactoprotein, consumer's such product of can more taking like a shot.
The specific embodiment
Therefore, in a preferred embodiment, will contain
-at least a butterfat and
The composition of the present invention of-at least a lactoprotein and/or at least a milk protein hydrolyzates is used for manufacturing and improves calcium absorption material.
Obtain lactoprotein by the albumen that separates the Ruzhong.For example, can be with casein, PROVON 190 and/or lactalbumin as simple component as lactoprotein of the present invention.
For milk protein fractions, except the whey of the Caseinum componemt that separates and/or separation, also can use the subfraction of these lactoproteins or the corresponding product behind the proteolysis.
Casein as naturally occurring albumen is the part of lactoprotein, and lactoprotein has 20% to be made of lactalbumin and about 80% to be made of casein approximately.The calcium in Ruzhong mainly combines with casein.Casein can be in conjunction with a large amount of calcium.This means that calcium is evenly distributed in the liquid and can accumulate in the bottom with sedimentary form.Yet casein has the shortcoming that goes out at acid pH sinking precipitation, makes the calcium of casein combination not be suitable for acidic products.
Existing in recent years various scientific research group studies calcium combine with caseic, and in this process, found the principle of calcium binding peptides.It is found that caseic some part combines well especially with calcium, and these parts have and protein bound phosphate.Produce the CPP (CPP) that combines well especially with calcium during casein hydrolysis.From chemical terms, CPP is the one group of peptide that is derived from casein or casein fragment and contains at least one phosphate.Present calcium solution by using CPP to obtain to clarify very much.Can be purchased this CPP (for example, CPP DMV) at present.
PROVON 190 (GMP) discharges from casein by the effect of renin in cheese production, and is found in after cheese production in the component that is called whey component.From chemical terms, as κ-caseic hydrophilic segment, PROVON 190 is the κ-casein fragment that has 106~169 amino acid sequence.Therefore PROVON 190 is also referred to as casein PROVON 190 or CMP.PROVON 190 exists with 11 kinds of different genetic variants, and wherein A and B are modal genetic variants.PROVON 190 can also contain the sugar chain that glucosides connects.There is 30%~50% GMP to contain the sugar chain that glucosides connects usually approximately.PROVON 190 does not contain any aromatic amino acid, and also not containing can be through its phosphate in conjunction with calcium.
The casein in Ruzhong and calcium form stable structure (being called casein micelles).CPP (CPP) and PROVON 190 (GMP) can discharge from casein by hydrolytic process.
For example, CPP and/or the GMP component of No. 102005033630.2, patent application DE can be used for application of the present invention, herein by with reference to incorporating its full content into the application.For this reason, can in extensive studies, detect the utilizability and the calcium associativity of better calcium.In addition, testing the protein content that is suitable for various milk protein fractions most in the test widely.These find to have drawn thus preferred protein content and with the corresponding proportion of butterfat.Therefore, preferred following albumen (having provided adult's consumption every day of recommendation in every kind of situation): GMP (5g~10g) and/or CPP (2g~10g) and/or casein (20g~40g) and/or be rich in the lactalbumin (40g~60g) of GMP (sweet).
What is interesting is, select or in addition, find that also lactalbumin and hydrolysate thereof are suitable for combining with calcium as another kind.Yet described combination is so effective not as the connection of above-mentioned casein and hydrolysate thereof.But lactalbumin and hydrolysate thereof can be used for the calcium combination equally effectively with enough a large amount of ratios; Just need to use the amount bigger than casein.Yet for many products, the amount of albumen is more inessential, so casein (and/or its hydrolysate) or intend can selecting to use according to required should being used for the lactalbumin (and/or its hydrolysate) of relatively large use.
For example, can use the lactalbumin that is purchased and hydrolysate thereof as lactoprotein.Yet, in the case, need compare about 2~4 times amount with required casein usually and realize good calcium combination.In the case, not all lactalbumin and hydrolysate thereof are all suitable equally.Find in the practice that known material as acid constituents (its isoelectric point is lower than pH 6.0) is optimum.
In composition of the present invention, the weight ratio between butterfat and the lactoprotein should be 0.0625~5, is preferably 0.5~4, is preferably 1~3 especially.This depend in each case albumen and the type of instant food.
The amount ratio that is used for improving the composition butterfat of the present invention (where applicable also has lactoprotein) that calcium absorbs can be in following ranges, and described scope is by not knowing by modulating the common dairy products that each newborn component makes.Theme of the present invention realizes by the composition that is made of concoction that still described concoction is by the newborn component manufacturing that obtains by different physical methods.
Modulation breast be defined as by in skimmed milk powder, add entry and add separately the liquid breast that butterfat obtains its degree that reaches the required fat content of setting (referring to Handbuch der Milch-undMolkereitechnik[Handbook of milk and dairy technology], Verlag Th.MannGmbH; Co.KG, 45894 Gelsenkirchen, 2003,412 pages).Similarly, modulation dairy products (for example ice cream) are too by the composition manufacturing that separates in advance.
In preparation, provide the combination of butterfat, lactoprotein and calcium more favourable in principle together, thereby because can select the best relation between the component to guarantee that best calcium absorbs so the most reliably.But, also can provide calcium with the form of corresponding nutritional supplement.
Therefore in another preferred embodiment, composition of the present invention is taken with the calcium of following form, and described form is at least a salt of checking and approving through food and/or medical rules.In the case, whenever take 1000mg calcium (this is simultaneously corresponding to adult's consumption every day for recommending), should take about 60g~about 400g butterfat/milk protein composition of the present invention simultaneously.Whenever taking 1000mg calcium preferably takes about 80g~about 150g, especially preferably takes about 100g composition of the present invention.Described at least a calcium salt can be contained in the identical product, promptly in the same administration form of composition of the present invention, also can take near the time of taking butterfat of the present invention (where applicable also has lactoprotein) composition as far as possible.
In principle, the calcium source and every day consumption should keep a certain ratio with amount every day of butterfat/milk protein composition.The salt of all calcics of checking and approving through food and/or medical rules can be used as the calcium source.For being without loss of generality, mention some calcium salts in the mode of example below: calcium carbonate, calcium chloride, calcium citrate, calcium gluconae, calcium glycerophosphate, calcium lactate, tricalcium orthophosphate, calcium oxide and/or calcium hydroxide.
In embodiments of the present invention, it is contemplated that interpolation mineral matter and/or trace element in composition of the present invention.For being without loss of generality, possible mineral matter or trace element have been mentioned in the mode of example below: magnesium, copper, iron, selenium, fluorine, iodine, manganese.For the calcium deposition problems in the anti-hemostatic tube, for example can in composition of the present invention, also add magnesium.In the case, can add all magnesium salts of checking and approving through alimentary codex.Recommendation is that the magnesium of 250mg is as dosage every day (be suitable for adult) with maximum.
Also preferably in compositions for use of the present invention, add vitamin, especially preferably add vitamin D, the again absorption of vitamin D collaborative promotion calcium in small intestine.Operable other supported one's family and have for example B family vitamin (B1, B6, B12), vitamin E, A or K.
In the preferred implementation of described composition, added such as Soluble Fibers such as FOS, galactooligosaccharide and/or phytosterols in application of the present invention.
For stablizing composition of the present invention, can use such as conventional emulsifiers such as lecithin, monoglyceride, diglycerides or through checking and approving the emulsifying agent that is used for food manufacturing.
Composition of the present invention both can be used as the additive in the food, also can be used as nutritional supplement or pharmaceutical preparation.
In principle, composition of the present invention can be used for making the reagent of liquid state, solid-state, powdery, bulk or any other state of aggregation.The state of aggregation decision administration form of product.Preferred oral is used.Yet, also can carry out (directly entering stomach), nasal feeding (entering stomach by nose) in the stomach, stomach and intestine outer (getting around gastronintestinal system directly enters in the body) or intravenous (directly entering vein) and use via probe.
Can make then as the product of bread and cheese or the product in the nutraceutical field.Yet, also can make the product that ranges medicine or self-medication field.
Can use composition of the present invention in many ways.Be without loss of generality its suitable especially milk product (comprising baby food), yogurt preparation, candy, powder, tablet, bulk form, rod, gel or emulsion as form of emulsion.
Typical application is to be used in dairy products, baby food, yoghourt (quark) and yogurt food, whey beverage, dessert, ice cream, fruit rod, tablet, capsule, spray or the unit-dose powder bag.
By reference the full content of described all applications of context, patent and communique is incorporated among the application.
Can think that even other embodiment is not provided, those skilled in the art also can be applied to foregoing description its maximum magnitude.Therefore, should think that described preferred implementation and embodiment are descriptive, and can never limit the scope of the invention.
Embodiment
Embodiment 1
The composition that provides for application of the present invention can contain composition as shown in table 1 below (adult's dosage every day of recommendation provides as an example).
Table 1: may the forming of the composition that provides for application of the present invention
Individual components | Weight ratio | Example (daily dose *) |
Butterfat component :-butter fat | About 1 | ?40.0g |
Milk protein fractions :-lactalbumin-CPP-PROVON 190 | About 1 about 0.06 about 0.12 | ?40.0g ?2.5g ?5.0g |
*) this daily dose should together take with 1000mg calcium.
Embodiment 2
Be fabricated to application of the present invention and the adult that provides uses beverage by following composition:
208.5g skimmed milk
81g sweet whey powder
37g cream
3.45g?CPP
This product contains enough calcium because of its raw material, thereby need not to add calcium compound again.
Dose is every part of 330ml, and should not surpass 800ml every day.
Embodiment 3
Be fabricated to application of the present invention and the infant formula (providing each composition) that provides by following composition according to the final infant formula of 100ml:
70.5 water (demineralizing)
The 21g skimmed milk
5.2g whey powder (demineralizing)
1.8g vegetable oil
2.5g lactose
1.7g butter
170mg GMP (PROVON 190)
90mg CPP (CPP)
Other composition: emulsifying agent, minerals and vitamins, these compositions must meet at the legal provision of Europe of infant formula instruction with about the German regulations of nutraceutical
Dose depends on infant age, and is about 1 liter/day.
Claims (14)
1. contain the application of the composition of at least a butterfat, described composition is used for manufacturing and improves calcium absorption reagent.
2. the application of composition as claimed in claim 1 is characterized in that, described butterfat is the newborn component without the physical separation of chemical modification.
3. the application of composition as claimed in claim 1 or 2 is characterized in that, described butterfat contains the esterification palmitic acid of 10 weight %~50 weight %, preferred 18 weight %~35 weight %, preferred especially 22 weight %~28 weight %.
4. the application of composition as claimed in claim 3 is characterized in that, makes the described palmitic acid of 20 weight %~75 weight %, preferred 35 weight %~50 weight %, preferred especially 40 weight %~45 weight % bit esterified at the sn-2 of glycerine.
5. as the application of each described composition in the claim 1~4, described composition comprises
-at least a butterfat and
-at least a lactoprotein and/or at least a milk protein hydrolyzates.
6. the application of composition as claimed in claim 5 is characterized in that, described lactoprotein is the newborn component of physical separation.
7. as the application of claim 5 or 6 described compositions, it is characterized in that the weight ratio of described butterfat and described lactoprotein is 0.0625~5, be preferably 0.5~4, more preferably 1~3.
8. as the application of each described composition in the claim 1~7, it is characterized in that described composition is used in combination with at least a salt of checking and approving through food and/or medical rules, wherein the composition of 60g~400g is used with the calcium of 1000mg.
9. as the application of each described composition in the claim 1~8, it is characterized in that at least a calcium salt is selected from the group of being made up of calcium carbonate, calcium chloride, calcium citrate, calcium gluconae, calcium glycerophosphate, calcium lactate, tricalcium orthophosphate, calcium oxide and calcium hydroxide.
10. as the application of each described composition in the claim 1~9, it is characterized in that, wherein added mineral matter, trace element and/or vitamin and emulsifying agent.
11. the application as each described composition in the claim 1~10 is characterized in that, has wherein added Soluble Fiber.
12. the application of composition as claimed in claim 11 is characterized in that, has wherein added FOS, galactooligosaccharide and/or phytosterol.
13. the application as each described composition in the claim 1~12 is characterized in that, has wherein added emulsifying agent.
14. as the application of each described composition in the claim 1~13, described composition is used as the additive in food, nutritional supplement or the pharmaceutical preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610173158.8A CN105962374A (en) | 2007-05-11 | 2008-05-07 | Composition application |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007022694.4 | 2007-05-11 | ||
DE102007022694A DE102007022694A1 (en) | 2007-05-11 | 2007-05-11 | Milk fat milk protein composition to improve calcium absorption |
PCT/EP2008/055597 WO2008138821A1 (en) | 2007-05-11 | 2008-05-07 | Milk fat-milk protein composition (preferably esterified with palmitic acid) for improving calcium absorption |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610173158.8A Division CN105962374A (en) | 2007-05-11 | 2008-05-07 | Composition application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101686726A true CN101686726A (en) | 2010-03-31 |
Family
ID=39645456
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880015561A Pending CN101686726A (en) | 2007-05-11 | 2008-05-07 | Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs |
CN201610173158.8A Pending CN105962374A (en) | 2007-05-11 | 2008-05-07 | Composition application |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610173158.8A Pending CN105962374A (en) | 2007-05-11 | 2008-05-07 | Composition application |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2152101A1 (en) |
CN (2) | CN101686726A (en) |
DE (1) | DE102007022694A1 (en) |
RU (1) | RU2468610C2 (en) |
UA (1) | UA99614C2 (en) |
WO (1) | WO2008138821A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106262925A (en) * | 2011-06-16 | 2017-01-04 | N·V·努特里奇亚 | The metabolism trace effect of custom-designed lipid composition |
CN107105738A (en) * | 2014-12-19 | 2017-08-29 | 雀巢产品技术援助有限公司 | Infant nutrition containing aminosal, ionized calcium and palmitic acid |
CN107105739A (en) * | 2014-12-19 | 2017-08-29 | 雀巢产品技术援助有限公司 | Infant nutrition containing aminosal and palmitic acid |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1399244B1 (en) * | 2009-07-31 | 2013-04-11 | Pharmarte S R L | FORMULATION OF BARRIER SPECIFIC FOR PREGNANCY. |
NL2019906B1 (en) * | 2017-11-14 | 2019-05-20 | Ausnutria Hyproca B V | Composition comprising a2 b-casein and a vegetable fat mixture |
DE102019205767A1 (en) * | 2019-04-23 | 2020-10-29 | Beiersdorf Ag | Deodorant or antiperspirant composition |
AU2021395877A1 (en) | 2020-12-11 | 2023-06-08 | Frieslandcampina Nederland B.V. | Fat blend suitable for infant nutrition |
WO2023232962A1 (en) | 2022-06-02 | 2023-12-07 | Frieslandcampina Nederland B.V. | Fat blend suitable for infant nutrition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2890379B2 (en) * | 1990-08-28 | 1999-05-10 | 雪印乳業株式会社 | Calcium absorption promoting nutrient, food and feed |
GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
NL9401958A (en) * | 1994-11-23 | 1996-07-01 | Friesland Brands Bv | Milk product enriched with eggshell flour. |
EP1062876A1 (en) * | 1999-02-25 | 2000-12-27 | Societe Des Produits Nestle S.A. | Caseinoglycomacropeptides as calcification agent |
US6620427B2 (en) * | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
IL158555A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
KR101368603B1 (en) * | 2005-04-27 | 2014-02-27 | 엔지모테크 리미티드 | Human Milk Fat Substitutes |
DE102005033630A1 (en) | 2005-07-19 | 2007-01-25 | Humana Gmbh | Calcium-peptide component |
-
2007
- 2007-05-11 DE DE102007022694A patent/DE102007022694A1/en not_active Ceased
-
2008
- 2008-05-07 EP EP08750120A patent/EP2152101A1/en not_active Ceased
- 2008-05-07 CN CN200880015561A patent/CN101686726A/en active Pending
- 2008-05-07 UA UAA200911185A patent/UA99614C2/en unknown
- 2008-05-07 CN CN201610173158.8A patent/CN105962374A/en active Pending
- 2008-05-07 RU RU2009144036/13A patent/RU2468610C2/en active
- 2008-05-07 WO PCT/EP2008/055597 patent/WO2008138821A1/en active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106262925A (en) * | 2011-06-16 | 2017-01-04 | N·V·努特里奇亚 | The metabolism trace effect of custom-designed lipid composition |
CN107105738A (en) * | 2014-12-19 | 2017-08-29 | 雀巢产品技术援助有限公司 | Infant nutrition containing aminosal, ionized calcium and palmitic acid |
CN107105739A (en) * | 2014-12-19 | 2017-08-29 | 雀巢产品技术援助有限公司 | Infant nutrition containing aminosal and palmitic acid |
Also Published As
Publication number | Publication date |
---|---|
CN105962374A (en) | 2016-09-28 |
DE102007022694A1 (en) | 2008-11-13 |
UA99614C2 (en) | 2012-09-10 |
RU2468610C2 (en) | 2012-12-10 |
WO2008138821A1 (en) | 2008-11-20 |
EP2152101A1 (en) | 2010-02-17 |
RU2009144036A (en) | 2011-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101686726A (en) | Be used to improve butterfat-milk protein composition (preferably using the palmitic acid esterification) that calcium absorbs | |
Park et al. | Physico-chemical characteristics of goat and sheep milk | |
O’Mahony et al. | Milk: an overview | |
Barłowska et al. | Nutritional value and technological suitability of milk from various animal species used for dairy production | |
ES2478869T3 (en) | Liquid enteral nutritional composition suitable for tube feeding | |
CN101636167B (en) | Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same | |
ES2764089T3 (en) | Nutritional composition that has lipophilic compounds with improved solubility and bioavailability | |
US20110223282A1 (en) | Nutritional composition with anti-regurgitation properties | |
WO2019104390A1 (en) | Milk substitute compositions | |
CN105188411A (en) | Method of enhancing bioavailability of DHA and other lipid-soluble nutrients | |
CN105188409A (en) | Infant nutritional product with RRR alpha-tocopherol | |
CN112998080A (en) | Infant formula milk powder added with yolk phospholipid, soybean phospholipid and milk phospholipid | |
ES2208256T5 (en) | COW MILK AND FEEDING PRODUCT OF A COW TO OBTAIN SUCH MILK. | |
WO2015187795A1 (en) | Nutritional compositions comprising a lipophilic active ingredient | |
JP6449648B2 (en) | Nutritional composition | |
WO2007140589A1 (en) | Dairy product | |
CN108157512A (en) | A kind of formula milk for strengthening 6 ~ 12 months infant's gastrointestinal functions | |
Park | Impact of goat milk and milk products on human nutrition. | |
Wells | Nutritional considerations in infant formula design | |
RU2311039C2 (en) | Product for enteral feeding | |
de la Fuente et al. | Sheep milk | |
Sharma et al. | Role of omega-3 fatty acids, conjugated linoleic acid and phytosterols in improving functionality of dairy products | |
JP2006022068A (en) | Serum lipid metabolism ameliorative agent | |
US20170367395A1 (en) | Infant nutrition with hydrolysed protein and palmitic acid | |
RU2311038C2 (en) | Product for enteral feeding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100331 |